Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Deep Fibromatosis/Desmoid TumorInterventions: Drug: Sorafenib Tosylate; Other: Placebo; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life AssessmentSponsor: National Cancer Institute (NCI)Recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Deep Fibromatosis/Desmoid TumorInterventions: Drug: Sorafenib Tosylate; Other: Placebo; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life AssessmentSponsor: National Cancer Institute (NCI)Recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Deep Fibromatosis/Desmoid TumorInterventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib TosylateSponsor: National Cancer Institute (NCI)Recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid TumorInterventions: Drug: sorafenib tosylate; Other: placebo; Other: laboratory biomarker analysis; Other: quality-of-life assessmentSponsor: National Cancer Institute (NCI)Recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid-Type FibromatosisInterventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib TosylateSponsor: National Cancer Institute (NCI)Recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid TumorInterventions: Drug: sorafenib tosylate; Other: placebo; Other: laboratory biomarker analysis; Other: quality-of-life assessmentSponsor: National Cancer Institute (NCI)Recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid-Type FibromatosisInterventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib TosylateSponsor: National Cancer Institute (NCI)Recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Deep Fibromatosis/Desmoid TumorInterventions: Drug: Sorafenib Tosylate; Other: Placebo; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life AssessmentSponsor: National Cancer Institute (NCI)Recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid-Type FibromatosisInterventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib TosylateSponsor: National Cancer Institute (NCI)Recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Deep Fibromatosis/Desmoid TumorInterventions: Drug: Sorafenib Tosylate; Other: Placebo; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life AssessmentSponsor: National Cancer Institute (NCI)Recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid-Type FibromatosisInterventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib TosylateSponsor: National Cancer Institute (NCI)Recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2014 Category: Research Source Type: clinical trials
